Last updated: August 17, 2026
Omontys Preservative Free, the U.S. brand for peginesatide injection, had a short commercial life. FDA approved the erythropoiesis-stimulating agent in March 2012 for anemia associated with chronic kidney disease in adult dialysis patients. Takeda and Affymax launched the product into a mature, price-sensitive market dominated by epoetin alfa and darbepoetin alfa. A voluntary recall in February 2013 followed reports of serious hypersensitivity reactions, including deaths. Commercial distribution ended, and the product generated no durable revenue stream after its first launch year.[1][2]
The commercial failure was driven by safety risk rather than weak clinical differentiation alone. Omontys offered once-monthly dosing, but its risk profile, limited market penetration, provider caution and the recall eliminated its ability to compete with established erythropoiesis-stimulating agents.
What was Omontys Preservative Free?
Omontys Preservative Free was a sterile, preservative-free injectable formulation of peginesatide, a synthetic peptide-based erythropoiesis-stimulating agent.
| Attribute |
Omontys Preservative Free |
| Active ingredient |
Peginesatide |
| Drug class |
Erythropoiesis-stimulating agent |
| Sponsor at approval |
Affymax |
| Commercial partner |
Takeda Pharmaceuticals |
| FDA approval |
March 27, 2012 |
| Initial indication |
Anemia due to chronic kidney disease in adult dialysis patients |
| Administration |
Intravenous or subcutaneous injection |
| Intended dosing advantage |
Once monthly |
| Preservative status |
Preservative-free, single-use presentation |
| Commercial status |
Withdrawn from the U.S. market after the 2013 recall |
The FDA-approved product was supplied in single-dose prefilled syringes and vials at several strengths. The preservative-free presentation was relevant to injectable safety and packaging, but it did not create a separate commercial market from the underlying peginesatide product.[1]
When did Omontys lose market exclusivity?
Omontys lost practical market exclusivity when Takeda and Affymax withdrew the product after the February 2013 recall. The commercial termination occurred before generic competition became the primary threat.
The relevant sequence was:
| Date |
Event |
Commercial effect |
| March 27, 2012 |
FDA approval |
U.S. launch eligibility |
| 2012 |
Takeda commercial launch |
Entry into the dialysis ESA market |
| February 2013 |
Voluntary recall announced |
Distribution and new-patient adoption halted |
| 2013 |
Commercial withdrawal |
Product revenue collapsed |
| 2014 |
Affymax insolvency and wind-down activities |
Original developer lost the ability to support the product |
| Later FDA records |
Product listed as withdrawn/discontinued |
No active U.S. commercial franchise |
Because Omontys was withdrawn after a safety event, the relevant economic endpoint was the recall, not ordinary patent expiry. The product did not progress to a normal loss-of-exclusivity cycle involving abbreviated new drug applications, Paragraph IV litigation or routine generic substitution.
What was the FDA regulatory status of Omontys?
Omontys is no longer an actively marketed FDA product. FDA approval was followed by a voluntary nationwide recall after reports of anaphylaxis and other serious hypersensitivity reactions.
The FDA safety communication identified serious hypersensitivity reactions, including anaphylaxis, hypotension, bronchospasm, cardiac arrest and death. The reported reactions occurred after administration of peginesatide, including in patients who had previously tolerated other ESAs.[2]
The regulatory consequences were severe:
- Hospitals and dialysis providers stopped routine use.
- Prescribers returned to established ESAs.
- The product’s once-monthly dosing advantage lost commercial value.
- Takeda and Affymax could not establish a credible relaunch pathway.
- Future investment in manufacturing, post-marketing studies and promotion became economically unattractive.
The recall also changed the risk-benefit assessment for peginesatide. ESA prescribing already required management of cardiovascular and thrombotic risks. Adding a rare but severe hypersensitivity signal increased the operational burden for dialysis providers and weakened the product’s position against familiar alternatives.
How did Omontys compare with competing anemia drugs?
Omontys entered a market with entrenched products, established reimbursement channels and extensive physician experience.
| Product |
Active ingredient |
Typical dosing advantage |
Competitive position |
| Omontys |
Peginesatide |
Once monthly |
Withdrawn after hypersensitivity reports |
| Epogen |
Epoetin alfa |
Frequent dosing |
Long-established dialysis standard |
| Procrit |
Epoetin alfa |
Frequent dosing |
Broad anemia franchise |
| Aranesp |
Darbepoetin alfa |
Less frequent than epoetin |
Established long-acting ESA |
| Mircera |
Methoxy polyethylene glycol-epoetin beta |
Extended dosing interval |
Competing long-acting ESA in applicable markets |
Omontys’ main product advantage was reduced injection frequency. Its principal commercial disadvantages were:
- limited prescriber familiarity at launch;
- a narrow initial dialysis indication;
- reimbursement and formulary competition;
- the established supply relationships of epoetin and darbepoetin manufacturers;
- the severe hypersensitivity signal;
- the absence of a viable post-recall relaunch.
The product also competed in a setting where dialysis organizations had significant purchasing leverage. Large providers could influence formulary selection, procurement and protocol adoption. A new ESA therefore needed either clear clinical superiority, a substantial cost advantage or a compelling operational benefit. Once the safety signal emerged, monthly dosing was insufficient to preserve demand.
What was the financial trajectory of Omontys?
Omontys followed a launch-to-recall financial trajectory rather than a conventional growth-to-expiry trajectory.
Prelaunch phase
Affymax developed peginesatide as a potential alternative to conventional ESAs. The company entered into a commercial relationship with Takeda, which provided development, regulatory and commercialization support. The arrangement transferred much of the commercial execution burden to a large pharmaceutical company, but it also created dependence on the product’s ability to achieve rapid dialysis-market adoption.
Affymax remained financially dependent on collaboration economics, milestone payments and future product revenue. That structure exposed the company to a sharp downside if the product failed after launch.
Launch phase
Omontys was approved in 2012 and entered a competitive U.S. ESA market. The product’s commercial thesis depended on:
- adoption by dialysis providers;
- conversion from established ESAs;
- acceptance of once-monthly dosing;
- stable reimbursement;
- controlled post-marketing safety performance.
Public company filings indicate that Omontys did not become a large revenue contributor before the recall. Affymax’s reported financial performance remained dominated by operating losses, collaboration arrangements and the cost of maintaining the business rather than by sustained product sales.[3]
Takeda’s public reporting did not establish Omontys as a major contributor to consolidated pharmaceutical revenue. The product was commercially immaterial relative to Takeda’s broader portfolio.
Recall phase
The February 2013 recall effectively terminated the revenue ramp. Inventory was removed, new prescriptions stopped and the product’s market share reverted to incumbent ESA suppliers.
The recall also impaired the value of:
- finished-goods inventory;
- promotional investments;
- manufacturing capacity;
- regulatory filings;
- commercialization infrastructure;
- future royalty and milestone expectations.
For Affymax, the impact was existential. The company announced workforce reductions and a wind-down after the recall, and it later entered bankruptcy proceedings. The company’s dependence on peginesatide meant that there was no diversified product base to offset the loss.[3][4]
Post-withdrawal phase
There was no meaningful post-withdrawal revenue trajectory in the United States. No established generic market developed, and no biosimilar pathway created a replacement revenue stream for the original sponsor.
The economic value of the product shifted from commercial sales to potential recovery value involving inventory, contractual rights, intellectual property and litigation claims. That value was materially lower than the value of an operating pharmaceutical franchise.
How strong was the Omontys patent estate?
The patent estate had limited practical value after the recall. Even a technically robust patent position cannot preserve substantial value when the product is commercially withdrawn for safety reasons.
The relevant distinction is between legal exclusivity and economic exclusivity:
- Legal exclusivity would have restricted unauthorized generic or competing use during the relevant patent and regulatory periods.
- Economic exclusivity disappeared when prescribers and dialysis providers stopped using the drug.
- A patent challenge was unnecessary for competitors because established ESAs already occupied the market.
- Any future peginesatide relaunch would have required substantial regulatory and safety investment, not simply freedom from generic competition.
Omontys did not develop a meaningful lifecycle franchise around additional indications, new delivery systems or differentiated formulations. The preservative-free formulation supported the approved injectable presentation but did not create a separate, durable market moat.
Were there Paragraph IV challenges or generic launch risks?
No material U.S. Paragraph IV challenge or commercial generic launch shaped the Omontys market. The product’s commercial withdrawal preceded the usual generic-entry cycle.
Generic-entry risk was therefore secondary to safety and discontinuation risk. A potential generic sponsor would have faced:
- A small or nonexistent active market.
- Regulatory questions surrounding the safety signal.
- Limited prescriber demand.
- Manufacturing and quality obligations for a sterile injectable.
- The need to support a product whose reference-market presence had collapsed.
- Potential liability and pharmacovigilance costs.
For these reasons, the primary market outcome was therapeutic substitution, not generic substitution.
What manufacturing and intellectual-property barriers affected Omontys?
Peginesatide was a complex peptide-based injectable rather than a conventional small-molecule tablet. Manufacturing required control of peptide synthesis, conjugation, purification, sterility, potency and product consistency.
The main barriers included:
- sterile injectable manufacturing capacity;
- validated analytical methods;
- control of impurities and aggregates;
- formulation and container-closure specifications;
- supply-chain reliability;
- post-marketing safety monitoring;
- regulatory documentation for any manufacturing change.
The preservative-free presentation reduced the relevance of preservative-related formulation differentiation. The core commercial obstacle was the safety profile of the active product, not the absence of a preservative.
What litigation, settlements or licensing issues affected Omontys?
The central business relationship was the Affymax-Takeda collaboration. Takeda commercialized Omontys while Affymax retained substantial dependence on the product’s success. After the recall, the collaboration no longer had the economics of a growing product launch.
The recall generated potential exposure involving patients, providers, commercial partners and investors. Affymax’s financial distress further complicated the value of contractual rights and litigation claims. The major strategic consequence was termination of the operating model supporting the product, rather than a market-shaping patent settlement.
No settlement agreement or Paragraph IV resolution established a delayed generic launch. The product’s commercial failure came from regulatory and safety events.
Which companies challenged Omontys commercially?
Omontys was challenged primarily by incumbent ESA suppliers rather than by generic manufacturers.
Amgen
Amgen’s Epogen and Aranesp franchises had established dialysis-provider relationships, manufacturing scale and protocol familiarity. These products were the most direct commercial comparators.
Johnson & Johnson
Procrit provided another established epoetin alfa option, particularly in settings where clinicians had extensive experience with conventional ESA treatment.
Roche
Mircera represented a long-acting ESA alternative in markets where it was approved and commercially available. Its extended dosing profile reduced the differentiation available from Omontys’ once-monthly schedule.
The competitive response did not require aggressive price disruption. Established products benefited from switching costs, clinical familiarity and existing procurement systems. The recall then removed Omontys from the competitive set.
What revenue exposure did Omontys create for Affymax and Takeda?
Affymax had concentrated product risk. Peginesatide was the company’s principal commercial asset, so the recall removed the main path to recurring revenue and undermined its ability to fund operations.
Takeda had limited consolidated revenue exposure because Omontys was small relative to its global portfolio. Its greater exposure involved:
- launch and promotional spending;
- inventory and supply commitments;
- regulatory and pharmacovigilance costs;
- reputational risk within the nephrology market;
- lost opportunity to build a monthly ESA franchise.
The recall was far more damaging to Affymax’s corporate valuation than to Takeda’s overall financial results.
What generic launch scenarios existed for Omontys?
The realistic generic scenarios were limited.
| Scenario |
Probability in commercial terms |
Reason |
| Immediate generic substitution |
Very low |
Product recall and lack of active market |
| Delayed generic after ordinary patent expiry |
Low |
No meaningful market remained |
| Reformulated peginesatide relaunch |
Low |
Required new safety and commercial investment |
| Therapeutic substitution to other ESAs |
High |
Established products were available |
| Biosimilar competition |
Not applicable to the original commercial outcome |
Peginesatide did not generate an active U.S. biosimilar market |
A future sponsor would have needed to address the hypersensitivity risk and demonstrate an acceptable benefit-risk profile. That requirement was substantially more demanding than filing a standard generic application against a stable reference product.
How does Omontys compare with successful ESA franchises?
Omontys had a favorable dosing concept but weak commercial durability.
| Factor |
Omontys |
Established ESAs |
| Dosing frequency |
Once monthly |
Daily, weekly or extended intervals depending on product |
| Market history |
Short launch period |
Long clinical and commercial history |
| Provider familiarity |
Limited |
High |
| Safety confidence |
Damaged by recall |
Established risk-management experience |
| Dialysis adoption |
Did not scale |
Embedded in treatment protocols |
| Generic or biosimilar pressure |
Not reached materially |
Increasing over time |
| Corporate support |
Affymax became insolvent |
Backed by diversified manufacturers |
The product’s failure illustrates the difference between dosing convenience and commercial defensibility. Once a severe safety signal affects an injectable used in a high-monitoring population, established alternatives gain share rapidly.
Key Takeaways
- Omontys Preservative Free was peginesatide, a once-monthly ESA approved by FDA in March 2012.
- The product was voluntarily recalled in February 2013 after serious hypersensitivity reactions, including deaths.
- Its commercial life ended before normal patent expiry or generic competition became relevant.
- Affymax carried concentrated financial exposure and entered a wind-down after the recall.
- Takeda’s consolidated revenue exposure was limited, but launch, inventory and compliance investments were impaired.
- The main competitors were Epogen, Procrit, Aranesp and, in relevant markets, Mircera.
- The preservative-free formulation did not generate a separate lifecycle franchise.
- Manufacturing complexity, injectable-product requirements and the safety signal made relaunch or generic entry unattractive.
- The dominant market effect was substitution to established ESAs, not Paragraph IV-driven generic entry.
- Omontys has no active U.S. commercial trajectory.
FAQs About Omontys Preservative Free
Is Omontys Preservative Free still available?
No. Omontys was withdrawn from the U.S. market after the February 2013 voluntary recall.
What caused the Omontys recall?
The recall followed reports of serious hypersensitivity reactions, including anaphylaxis, cardiovascular events and deaths associated with peginesatide administration.[2]
Was Omontys a biosimilar?
No. Omontys was an original peginesatide ESA product. It was not a biosimilar to epoetin alfa or darbepoetin alfa.
Did Omontys have a successful once-monthly dosing strategy?
The once-monthly regimen was a potential commercial advantage, but the product did not achieve sustained market adoption because of the safety-related withdrawal.
Did Affymax continue selling other drugs after Omontys failed?
No. Affymax was substantially dependent on peginesatide and moved toward workforce reductions, operational wind-down and bankruptcy-related proceedings after the recall.[3][4]
References
-
U.S. Food and Drug Administration. (2012). Omontys (peginesatide) injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (2013, February 23). FDA drug safety communication: FDA recommends stopping use of Omontys (peginesatide) injection. FDA.
-
Affymax, Inc. (2013). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
Affymax, Inc. (2014). Form 8-K and bankruptcy-related filings. U.S. Securities and Exchange Commission.
-
Takeda Pharmaceutical Company Limited. (2013). Annual report. Takeda Pharmaceutical Company Limited.
